Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 419

1.

FTY720 (fingolimod) for relapsing multiple sclerosis.

Horga A, Montalban X.

Expert Rev Neurother. 2008 May;8(5):699-714. doi: 10.1586/14737175.8.5.699. Review.

PMID:
18457527
[PubMed - indexed for MEDLINE]
2.

Fingolimod for the treatment of relapsing multiple sclerosis.

Jeffery DR, Markowitz CE, Reder AT, Weinstock-Guttman B, Tobias K.

Expert Rev Neurother. 2011 Feb;11(2):165-83. doi: 10.1586/ern.10.193. Epub 2010 Dec 16. Review.

PMID:
21158700
[PubMed - indexed for MEDLINE]
3.

[FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis].

Klatt J, Hartung HP, Hohlfeld R.

Nervenarzt. 2007 Oct;78(10):1200-8. Review. German.

PMID:
17668161
[PubMed - indexed for MEDLINE]
4.

Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.

Kowarik MC, Pellkofer HL, Cepok S, Korn T, Kümpfel T, Buck D, Hohlfeld R, Berthele A, Hemmer B.

Neurology. 2011 Apr 5;76(14):1214-21. doi: 10.1212/WNL.0b013e3182143564.

PMID:
21464424
[PubMed - indexed for MEDLINE]
5.

Fingolimod for relapsing multiple sclerosis: an update.

Horga A, Castilló J, Montalban X.

Expert Opin Pharmacother. 2010 May;11(7):1183-96. doi: 10.1517/14656561003769866. Review.

PMID:
20367536
[PubMed - indexed for MEDLINE]
6.

Fingolimod: a novel immunosuppressant for multiple sclerosis.

Brown BA, Kantesaria PP, McDevitt LM.

Ann Pharmacother. 2007 Oct;41(10):1660-8. Epub 2007 Sep 4. Review.

PMID:
17785617
[PubMed - indexed for MEDLINE]
7.

[New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].

Chiba K.

Yakugaku Zasshi. 2009 Jun;129(6):655-65. Review. Japanese.

PMID:
19483408
[PubMed - indexed for MEDLINE]
Free Article
8.

Current perspectives on FTY720.

Martini S, Peters H, Böhler T, Budde K.

Expert Opin Investig Drugs. 2007 Apr;16(4):505-18. Review.

PMID:
17371198
[PubMed - indexed for MEDLINE]
9.

Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.

Scott LJ.

CNS Drugs. 2011 Aug;25(8):673-98. doi: 10.2165/11207350-000000000-00000. Review.

PMID:
21790210
[PubMed - indexed for MEDLINE]
10.

Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.

Lee CW, Choi JW, Chun J.

Arch Pharm Res. 2010 Oct;33(10):1567-74. doi: 10.1007/s12272-010-1008-5. Epub 2010 Oct 30. Review.

PMID:
21052934
[PubMed - indexed for MEDLINE]
11.

Central nervous system-directed effects of FTY720 (fingolimod).

Miron VE, Schubart A, Antel JP.

J Neurol Sci. 2008 Nov 15;274(1-2):13-7. doi: 10.1016/j.jns.2008.06.031. Epub 2008 Aug 3. Review.

PMID:
18678377
[PubMed - indexed for MEDLINE]
12.

Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.

Hiestand PC, Rausch M, Meier DP, Foster CA.

Prog Drug Res. 2008;66:361, 363-81. Review.

PMID:
18416311
[PubMed - indexed for MEDLINE]
13.

FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.

Baumruker T, Billich A, Brinkmann V.

Expert Opin Investig Drugs. 2007 Mar;16(3):283-9. Review.

PMID:
17302523
[PubMed - indexed for MEDLINE]
14.

Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.

Vasiliou S.

Drugs Today (Barc). 2010 May;46(5):315-25. doi: 10.1358/dot.2010.46.5.1497556. Review.

PMID:
20517533
[PubMed - indexed for MEDLINE]
15.

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group.

N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20.

PMID:
20089954
[PubMed - indexed for MEDLINE]
Free Article
16.

Clinical pharmacokinetics of fingolimod.

David OJ, Kovarik JM, Schmouder RL.

Clin Pharmacokinet. 2012 Jan 1;51(1):15-28. doi: 10.2165/11596550-000000000-00000. Review.

PMID:
22149256
[PubMed - indexed for MEDLINE]
17.

Fingolimod is a potential novel therapy for multiple sclerosis.

Aktas O, Küry P, Kieseier B, Hartung HP.

Nat Rev Neurol. 2010 Jul;6(7):373-82. doi: 10.1038/nrneurol.2010.76. Epub 2010 Jun 15. Review.

PMID:
20551946
[PubMed - indexed for MEDLINE]
18.

[A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].

Chiba K.

Nihon Rinsho Meneki Gakkai Kaishi. 2009 Apr;32(2):92-101. Review. Japanese.

PMID:
19404007
[PubMed - indexed for MEDLINE]
Free Article
19.

Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.

Dev KK, Mullershausen F, Mattes H, Kuhn RR, Bilbe G, Hoyer D, Mir A.

Pharmacol Ther. 2008 Jan;117(1):77-93. Epub 2007 Sep 8. Review.

PMID:
17961662
[PubMed - indexed for MEDLINE]
20.

Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.

Mehling M, Johnson TA, Antel J, Kappos L, Bar-Or A.

Neurology. 2011 Feb 22;76(8 Suppl 3):S20-7. doi: 10.1212/WNL.0b013e31820db341. Review.

PMID:
21339487
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk